Document Detail

Anti-citrullinated peptide antibodies and the progression of radiographic joint erosions in patients with early rheumatoid arthritis treated with FIN-RACo combination and single disease-modifying antirheumatic drug strategies.
MedLine Citation:
PMID:  21640044     Owner:  NLM     Status:  Publisher    
OBJECTIVES: To evaluate the impact of antibodies to cyclic citrullinated peptide (ACPAs) on radiographic progression in patients with early rheumatoid arthritis (RA) initially treated either with a combination of 3 disease-modifying antirheumatic drugs (DMARDs) or with a single DMARD. METHODS: This study included 129 patients with early active RA initially randomised to treatment either with a combination of methotrexate, sulfasalazine, hydroxychloroquine, and prednisolone (FIN-RACo) (n=69) or with a single DMARD (initially sulfalasalazine) with or without prednisolone (SINGLE) (n=60). After 2 years, the use of DMARDs and prednisolone became unrestricted. Radiographic progression in hands and feet was assessed at baseline and at 1, 2, 3, 4 and 5 years. ACPAs at baseline were determined with enzyme immunoassay. RESULTS: ACPAs were positive in 92 (71%) patients. ACPA-positive vs. negative patients were more frequently rheumatoid factor (RF) positive (83% vs. 22%, p<0.001) and had an erosive disease (54% vs. 22%, p<0.001) at baseline. The presence of ACPA was associated with radiographic progression in FIN-RACo group even when the impact of RF was controlled; the radiographic progression was remarkably slower in ACPA-negative than in ACPA-positive cases (RF adjusted change over time between groups p=0.034). In the SINGLE group, the radiographic changes progressed parallel in ACPA-negative and positive patients. CONCLUSIONS: Most ACPA-positive RA patients have joint erosions already at diagnosis. ACPA positivity in early RA was related to radiographic progression even in patients treated initially with the FIN-RACo regimen. The initial FIN-RACo therapy seems to slow down the progression of joint damage in ACPA-negative patients.
Anu Mustila; Markku Korpela; Anna-Maija Haapala; Hannu Kautiainen; Leena Laasonen; Timo Möttönen; Marjatta Leirisalo-Repo; Jorma Ilonen; Salme Järvenpää; Reijo Luukkainen; Pekka Hannonen
Related Documents :
21607034 - Radionuclide imaging with human polyclonal immunoglobulin (tc-hig) and bone scan in pat...
16495144 - Clinical correlates of quantitative eeg alterations in alcoholic patients.
12488784 - Clinical and radiologic correlates of frontal intermittent rhythmic delta activity.
20952634 - Functional isolation within the cerebral cortex in the vegetative state: a nonlinear me...
23620634 - Head and neck cancer. an aetiopathogenetic study of non-endemic lymphoepithelioma.
24232504 - Antiphospholipid syndrome nephropathy (apsn) in patients with lupus nephritis: a retros...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-5-31
Journal Detail:
Title:  Clinical and experimental rheumatology     Volume:  -     ISSN:  0392-856X     ISO Abbreviation:  -     Publication Date:  2011 May 
Date Detail:
Created Date:  2011-6-6     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8308521     Medline TA:  Clin Exp Rheumatol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Pirkanmaa Hospital District, Centre for Laboratory Medicine, Tampere, Finland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Baseline characteristics of the population enrolled in the Italian Observational Study on Severe Ost...
Next Document:  Association of interleukin-2, interleukin-4 and transforming growth factor-beta gene polymorphisms w...